Видео ютуба по тегу Dr. Constantine Tam

Долгосрочные результаты лечения занубрутинибом у пациентов с ХЛЛ — д-р Константин Там
Долгосрочные результаты лечения занубрутинибом у пациентов с ХЛЛ — д-р Константин Там
Dr. Constantine Tam on the Role of Zanubrutinib in Frontline CLL Treatment,
Dr. Constantine Tam on the Role of Zanubrutinib in Frontline CLL Treatment,
Lymph Node Size and Outcomes After Ibrutinib-Venetoclax - Dr. Constantine Tam
Lymph Node Size and Outcomes After Ibrutinib-Venetoclax - Dr. Constantine Tam
Dr. Constantine S. Tam on BCL2 Inhibitors Compared to Ibrutinib, Idelalisib
Dr. Constantine S. Tam on BCL2 Inhibitors Compared to Ibrutinib, Idelalisib
Dr Constantine Tam: Living with Chronic Lymphocytic Leukaemia (CLL) Part 1 of 4
Dr Constantine Tam: Living with Chronic Lymphocytic Leukaemia (CLL) Part 1 of 4
Introducing Professor Constantine Tam: Research & Education Lead, Haematology
Introducing Professor Constantine Tam: Research & Education Lead, Haematology
Dr Constantine Tam Discusses the Benefits of Zanubrutinib on Cardiac Effects
Dr Constantine Tam Discusses the Benefits of Zanubrutinib on Cardiac Effects
Next-Generation BTK Inhibitor for Chronic Lymphocytic Leukemia (CLL) - Dr. Constantine Tam ASH 2021
Next-Generation BTK Inhibitor for Chronic Lymphocytic Leukemia (CLL) - Dr. Constantine Tam ASH 2021
Dr Constantine Tam: Living with Chronic Lymphocytic Leukaemia (CLL) Part 2 of 4
Dr Constantine Tam: Living with Chronic Lymphocytic Leukaemia (CLL) Part 2 of 4
Занубрутиниб с делецией (17p) при хроническом лимфолейкозе (ХЛЛ) и склерозе лимфобластного лейкоз...
Занубрутиниб с делецией (17p) при хроническом лимфолейкозе (ХЛЛ) и склерозе лимфобластного лейкоз...
Constantine Tam: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia
Constantine Tam: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia
Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL
Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL
Constantine Tam, MBBS, MD, compares the benefits of zanubrutinib to other BTK inhibitors
Constantine Tam, MBBS, MD, compares the benefits of zanubrutinib to other BTK inhibitors
Constantine Tam, MBBS, MD, regarding the data that lead to the recent FDA approval of zanubrutinib
Constantine Tam, MBBS, MD, regarding the data that lead to the recent FDA approval of zanubrutinib
Dr Constantine Tam: Living with Chronic Lymphocytic Leukaemia (CLL) Part 4 of 4
Dr Constantine Tam: Living with Chronic Lymphocytic Leukaemia (CLL) Part 4 of 4
Assessing BGB-11417, a novel BCL2 inhibitor, in NHL
Assessing BGB-11417, a novel BCL2 inhibitor, in NHL
Dr Constantine Tam: Living with Chronic Lymphocytic Leukaemia (CLL) Part 3 of 4
Dr Constantine Tam: Living with Chronic Lymphocytic Leukaemia (CLL) Part 3 of 4
A Noncovalent LYN / BTK Dual Inhibitor for Relapsed B Cell Cancers - Dr. Constantine Tam
A Noncovalent LYN / BTK Dual Inhibitor for Relapsed B Cell Cancers - Dr. Constantine Tam
Zanubrutinib Combined with Venetoclax for CLL Patients with Deletion 17p - Dr. Constantine Tam
Zanubrutinib Combined with Venetoclax for CLL Patients with Deletion 17p - Dr. Constantine Tam
Dr. Tam on Zanubrutinib Vs Ibrutinib Research in Mantle Cell Lymphoma
Dr. Tam on Zanubrutinib Vs Ibrutinib Research in Mantle Cell Lymphoma
Dr. Tam on the Toxicities of Ibrutinib Plus Venetoclax in MCL
Dr. Tam on the Toxicities of Ibrutinib Plus Venetoclax in MCL